Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Health Hematology Oncology at Hollings Cancer Center, shared a post on X:
“Interesting move in the new NCCN guidelines: ADCs are now listed as a first-line option in mTNBC, even before FDA approval. Highlights how rapidly the treatment landscape is evolving.”
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared this post, adding:
“Not sure of the reasoning behind the different recommendation categories for SG and Dato-DXd in PDL1- disease, despite OS advantage with Dato-DXd?”
Rita Nanda, Director of Breast Oncology at UChicago Medicine, commented:
“TB-02 is not yet published. I suspect that is the reason for the different recommendation category. Once published in peer reviewed journal, I suspect it will have a similar recommendation. OS advantage differences likely just due to lack of as much x-over.”
More posts featuring Abi Siva and Paolo Tarantino.